Tag - Pyramid Biosciences

Pyramid Biosciences Announces Initial Closing of Series B Financing for Clinical Program Acceleration

Ziad2022-11-25T14:00:11-05:00Pyramid Biosciences, Inc., a clinical stage, biotechnology company developing a portfolio of precision therapies targeting a wide range of molecularly-defined diseases, today announced the initial close of its Series B financing. The financing will support the clinical development of multiple programs focused on novel tropomyosin receptor kinase (TRK) modulators. The funding round was led by Oracle Investment Management, Inc., along with support from Adage Capital Management, Averill Master Fund, Ltd., J.W. Childs Associates L.P. as well as several other investors....

Pyramid Biosciences Announces First Patients Dosed in Phase 1 Clinical Program for Dermatology

Ziad2022-11-25T14:00:30-05:00 Pyramid Biosciences, Inc., a clinical-stage, biotechnology company developing novel precision therapies, announced that it has commenced a Phase 1 clinical study for its therapeutic candidate PBI-100, a first-in-class topical treatment targeting mild to moderate psoriasis in patients. Read more >>

VC funding update: Boston startups and tech firms raised $1.3B in August

Ziad2022-11-25T14:02:27-05:00 The VC summer slowdown may be real after all. Last month, Boston-area startups and tech firms raised a collective $1.3B—a formidable number, but nothing approximating July’s $6.9B. Waltham-based Pyramid Biosciences raised $8.8M in equity in an $18M funding round, according to an SEC filing. Read more >>

Pyramid Biosciences Announces Exclusive Global License of AstraZeneca TRK Program for Dermatology and Inflammatory Diseases

Ziad2022-11-25T14:04:53-05:00 Pyramid Biosciences, Inc. (www.pyramidbio.com), a Boston-based biotechnology company developing new therapies focused on the modulation of cell surface receptors today announced it has entered into an exclusive, worldwide licensing agreement with AstraZeneca PLC for the development and commercialization rights to a novel Tropomyosin receptor kinase (TRK) modulator, PBI-100. Read more >>